Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Timing is everything: new study tests when to give painkiller for safer knee surgery in seniors

NCT ID NCT07271849

Symptom relief Sponsor: Qianfoshan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving the painkiller nalbuphine at different times during knee replacement surgery can better control pain and keep the heart stable in patients aged 65 and older. About 162 participants will receive nalbuphine either during anesthesia or after cement placement. The goal is to find the best timing to improve recovery and reduce complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nalbuphine
What this could lead to
If successful, this could help doctors choose the best time to give nalbuphine during knee replacement to reduce pain and keep the heart stable in older patients.
What could go wrong
This is a small, single-center Phase 4 trial. Results may not apply to all patients, and nalbuphine may not prove better than standard timing for pain or heart stability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 162 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All study participants voluntarily enrolled in the trial and provided written informed consent after being fully informed of the trial's purpose and significance * Participants underwent unilateral total knee arthroplasty under general anesthesia * Elderly participants (age ≥ 65 years), regardless of gender * Body mass index (BMI) ranging from 18 kg/m² to 30 kg/m² * Absence of psychiatric disorders, normal consciousness, and ability to communicate effectively * American Society of Anesthesiologists (ASA) physical status classification I-III; * No contraindications to the study medications Exclusion Criteria: * Study participants with uncontrolled or untreated hypertension (resting systolic/diastolic blood pressure \>180/100 mmHg) * Individuals with severe respiratory diseases * Subjects with abnormal liver or renal function (ALT and/or AST \>2.5 times the upper limit of normal, total bilirubin \>1.5 times the upper limit of normal, serum creatinine \>1.5 times the upper limit of normal) * Individuals with a history of drug abuse, illicit drug use, or alcohol abuse, where alcohol abuse is defined as an average daily alcohol intake exceeding 2 units (1 unit = 360 mL of beer, 45 mL of 40% alcohol by volume spirits, or 150 mL of wine)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemodynamics are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoarthritis Pain, Postoperative rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemodynamics Postoperative pain, acute Total knee arthroplasty (TKA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University,

    RECRUITING

    Jinan, Shandong, 250000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.